Shanghai Henlius Biotech Inc (2696)

Currency in HKD
74.25
+0.90(+1.23%)
Closed·
2696 Scorecard
Full Analysis
Trading at a low P/E ratio relative to near-term earnings growth
2696 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
71.1074.25
52 wk Range
15.2076.00
Key Statistics
Bid/Ask
74.00 / 74.25
Prev. Close
73.35
Open
73.2
Day's Range
71.1-74.25
52 wk Range
15.2-76
Volume
1.11M
Average Volume (3m)
1.33M
1-Year Change
227.81%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
2696 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
61.59
Downside
-17.05%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Shanghai Henlius Biotech Inc Company Profile

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn’s disease, and pediatric Crohn’s disease; and HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and recurrent non-small cell lung cancer. The company also develops HANSIZHUANG, a serplulimab injection to treat colorectal cancer, gastric carcinoma, and limited-stage small cell lung cancer; HLX04-O, an anti-VEGF monoclonal antibody injection for wet age-related macular degeneration; HLX22 to treat of metastatic gastroesophageal junction cancer and gastric cancer; HLX6018 to treat idiopathic pulmonary fibrosis; HLX22, HLX42, HLX43, and HLX53 to treat solid tumors; HLX11 to treat breast cancer; HLX14 to treat osteoporosis; and HLX15 for multiple myeloma. The company operates in Mainland China, the Asia Pacific, North and South America, Europe, and Oceania. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical Development Co., Ltd.

Employees
3515
Market
Hong Kong

Compare 2696 to Peers and Sector

Metrics to compare
2696
Peers
Sector
Relationship
P/E Ratio
45.0x−33.5x−0.5x
PEG Ratio
0.880.170.00
Price/Book
12.3x7.2x2.6x
Price / LTM Sales
6.5x17.0x3.3x
Upside (Analyst Target)
−16.1%−12.1%43.4%
Fair Value Upside
Unlock−16.7%7.1%Unlock

Analyst Ratings

4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 61.59
(-17.05% Downside)

Earnings

Latest Release
Apr 15, 2025
EPS / Forecast
0.80 / --
Revenue / Forecast
2.98B / --
EPS Revisions
Last 90 days

2696 Income Statement

People Also Watch

561.00
0700
-1.06%
91.25
1801
-0.16%
160.40
9926
+1.91%
522.04
MSFT
+0.23%
222.69
AMZN
-0.20%

FAQ

What Stock Exchange Does Henlius Biotech Trade On?

Henlius Biotech is listed and trades on the Hong Kong Stock Exchange stock exchange.

What Is the Stock Symbol for Henlius Biotech?

The stock symbol for Henlius Biotech is "2696."

What Is the Henlius Biotech Market Cap?

As of today, Henlius Biotech market cap is 40.35B.

What Is Henlius Biotech's Earnings Per Share (TTM)?

The Henlius Biotech EPS (TTM) is 1.51.

From a Technical Analysis Perspective, Is 2696 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Henlius Biotech Stock Split?

Henlius Biotech has split 0 times.

How Many Employees Does Henlius Biotech Have?

Henlius Biotech has 3515 employees.

What is the current trading status of Henlius Biotech (2696)?

As of 10 Aug 2025, Henlius Biotech (2696) is trading at a price of 74.25, with a previous close of 73.35. The stock has fluctuated within a day range of 71.10 to 74.25, while its 52-week range spans from 15.20 to 76.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.